Johnson & Johnson: Depressive Disorder, Treatment-Resistant trials

The registry lists 25 Depressive Disorder, Treatment-Resistant studies with Johnson & Johnson as lead sponsor. 1 are open to participants now and 12 have results posted.

Phase 1 1Phase 2 5Phase 3 11Phase 4 3No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant DepressionRecruitingNCT07716098Phase 3
• A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray TreatmentCompletedNCT04829318Phase 4Results posted
• A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant DepressionCompletedNCT04599855Phase 4Results posted
• A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant DepressionCompletedNCT03434041Phase 3Results posted
• A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant DepressionCompletedNCT02918318Phase 2Results posted
• A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant DepressionCompletedNCT02782104Phase 3Results posted
• A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant DepressionCompletedNCT02497287Phase 3Results posted
• A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant DepressionCompletedNCT02493868Phase 3Results posted
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant DepressionCompletedNCT02422186Phase 3Results posted
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant DepressionCompletedNCT02418585Phase 3Results posted
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant DepressionCompletedNCT02417064Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant DepressionCompletedNCT01998958Phase 2Results posted
• A Study of Ketamine in Patients With Treatment-resistant DepressionCompletedNCT01627782Phase 2Results posted
• A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant DepressionCompletedNCT07053345Phase 4
• A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant DepressionWithdrawnNCT05268497Phase 1
• An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment AlternativesCompletedNCT04476446Phase 3
• A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant DepressionWithdrawnNCT03852160Phase 3
• Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD)Approved for marketingNCT03829579
• Treatment-Resistant Depression Cohort in EuropeCompletedNCT03373253
• Treatment Resistant Depression in America LatinaCompletedNCT03207282
• An Epidemiology Study of Treatment Resistant Depression in the United States (US)CompletedNCT03109002
• Epidemiology of Treatment Resistant Depression in TaiwanCompletedNCT02691520
• A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant DepressionCompletedNCT01640080Phase 2
• Safety and Efficacy of EVT 101 in Treatment-Resistant DepressionTerminatedNCT01128452Phase 2
• A Study of the Effectiveness and Safety of Risperidone to Augment SSRI Therapy in Patients With Treatment-resistant DepressionCompletedNCT00044681Phase 3